<DOC>
	<DOCNO>NCT00739219</DOCNO>
	<brief_summary>This study design show pharmacotherapy guide eNO clinical standard care produce superior outcome trial-based therapy guide clinical standard care alone .</brief_summary>
	<brief_title>Management Asthma Patients Guided Exhaled Nitric Oxide ( eNO )</brief_title>
	<detailed_description>Patients persistent , moderate severe asthma randomize receive therapy guide either eNO clinical standard care ( eNO group ) clinical standard care ( control group ) . An eNO treatment algorithm establish patient eNO group Baseline ( Visit 1 ) . Enrollment estimate six month follow period twelve month .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<criteria>Preexisting diagnosis asthma Persistent , moderate severe asthma classify NAEPP Suboptimally control asthma Initiated ICS therapy least past 30 day history improvement asthma control steroid Active cigarette smoking â‰¥ 10 packyears smoke history Xolair take past 6 month prior enrollment Oral prednisone take last 4 week prior enrollment Cystic Fibrosis , COPD , ciliary dyskinesia , chest wall deformity scoliosis Subject currently enrol another investigational drug study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Asthma</keyword>
	<keyword>inflammation</keyword>
	<keyword>nitric oxide</keyword>
	<keyword>eNO</keyword>
	<keyword>FENO</keyword>
</DOC>